Upgrade to SI Premium - Free Trial

Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)

June 22, 2026 9:29 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $188.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented, "At ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments